imetelstat
17 days ago
imetelstat
17 days ago
steve
19 days ago
gern
25 days ago
#gern Regarding Safety:
“The IMerge Phase 3 efficacy results illustrate the depth, breadth and durability of transfusion independence potentially achievable with Imetelstat treatment, which could be practice changing, if approved. These results are especially encouraging, because today we have limited treatment options for lower risk MDS patients that provide broad and durable transfusion independence,” said Uwe Platzbecker, M.D., a principal investigator of IMerge Phase 3. “With regards to the safety results, cytopenias were manageable and reversible. Importantly for hematologists, who are accustomed to managing cytopenias, clinical consequences were limited and similar to placebo treated patients. As a once per month out-patient IV therapy, Imetelstat will hopefully become a novel treatment option for lower risk MDS patients in the near future.” https://seekingalpha.com/n...
Read more
gern
25 days ago
#gern This is just the first major victory. MF phase 3 is now very likely to repeat or exceed the overall survival shown in phase 2. This drug will be soon approved in the US and EU. Soon a partner in the EU and then testing in AML. BTW if you have any concerns about safety, read the actual data and compare to competing drugs. The distraction from AF is purely sour grapes because he has been proven wrong and just playing his usual games. We won, he’s a sore loser. https://seekingalpha.com/n... https://seekingalpha.com/n...
Read more
steve
25 days ago
Read more

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.